TGFB1 and breast carcinoma: In fact, TGF-β signaling blockade by some modalities [i.e., over- expression of either a dominant-negative form of TGF-β receptor type II (50) or SMAD7 (51) in breast cancer cells (52, 53) was shown to be effective in reducing bone metastases.